Multilingual content from IBKR

Close Navigation
Learn more about IBKR accounts

Child’s Play

Posted November 3, 2021 at 11:05 am

What’s going on?

Pfizer reported better-than-expected results on Tuesday, and the pharma giant’s kid-friendly vaccination campaign should only help keep that going.

What does this mean?

Pfizer’s had stiff competition throughout the pandemic in the form of Moderna, AstraZeneca, and Johnson & Johnson, but lately it’s managed not to succumb to any of the supply chain side effects that have afflicted its vaccine rivals. It’s also not been responsible for as many regular old side effects, making it the top choice for wary vaccine-takers everywhere. That’s put the company in prime position to increase its market share in the US and Europe, which it’s done by 18% and 10% respectively since April.

That might be why revenue from Pfizer’s vaccine – which makes up nearly 55% of the firm’s total – came in better than expected last quarter, and why it beat overall revenue expectations too. The company’s feeling so healthy, in fact, that it upped its full-year outlook for vaccine sales to $36 billion – more than double the $15 billion it expected back in February.

Why should I care?

The bigger picture: The sooner everyone’s vaccinated, the better.

Pfizer’s expecting next year to be big for vaccine sales too, especially as it expands global distribution and provides both doses for kids and boosters for the already vaccinated. The company also said it’d be upping supply to lower-income regions – including Africa, where only 6% of the population is vaccinated – going forward, which is essential if the global economy is ever going to start firing on all cylinders again.

For you personally: There are other ways to profit from vaccines.

Pfizer’s stock is up 34% in the last year, so you’re probably too late if you were hoping to benefit from the success of its vaccine. But it’s not the only way you can profit from the ongoing demand: every business involved in the vaccination process stands to benefit, from the chemical manufacturers that mass produce the doses to the transport companies that get them wherever they need to be.

Originally Posted on November 2, 2021 – Child’s Play

Disclosure: Interactive Brokers

Information posted on IBKR Campus that is provided by third-parties does NOT constitute a recommendation that you should contract for the services of that third party. Third-party participants who contribute to IBKR Campus are independent of Interactive Brokers and Interactive Brokers does not make any representations or warranties concerning the services offered, their past or future performance, or the accuracy of the information provided by the third party. Past performance is no guarantee of future results.

This material is from Finimize and is being posted with its permission. The views expressed in this material are solely those of the author and/or Finimize and Interactive Brokers is not endorsing or recommending any investment or trading discussed in the material. This material is not and should not be construed as an offer to buy or sell any security. It should not be construed as research or investment advice or a recommendation to buy, sell or hold any security or commodity. This material does not and is not intended to take into account the particular financial conditions, investment objectives or requirements of individual customers. Before acting on this material, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.

IBKR Campus Newsletters

This website uses cookies to collect usage information in order to offer a better browsing experience. By browsing this site or by clicking on the "ACCEPT COOKIES" button you accept our Cookie Policy.